|
1. BIOLOGIE
|
|
|
Multi-omics Study of Gut Microbiota in Colorectal Cancer [ESMO]
|
|
|
|
|
|
A group of Japanese scientists reported on 6 June 2019 in the Nature Medicine findings from a large-cohort multi-omics study which indicate that shifts in the microbiome and metabolome occur from the very early stages of the development of colorectal cancer. The findings are of possible aetiological and diagnostic importance.
|
|
|
|
|
|
|
Transmissible cancer and the evolution of sex [PLOS Biology]
|
|
|
|
|
|
Given the omnipresence of oncogenic processes in multicellular organisms, together with the fact that transmissible cancer cells can have dramatic effects on their host fitness, our scenario suggests that the benefits of sex and concomitant recombination will be large and permanent, explaining why sexual reproduction is, despite its costs, the dominant mode of reproduction among eukaryotes.
|
|
|
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
Not silent at all [DKFZ]
|
|
|
|
|
|
Scientists from the German Cancer Consortium, German Cancer Research Center, and the University of Freiburg have now created a comprehensive database of all synonymous mutations ever found in cancer. This is a "reference book" that provides cancer researchers with all available information on each of these supposedly "silent" mutations at a glance.
|
|
|
|
|
|
|
1.4 BIOLOGIE - TECHNOS
|
|
|
|
2.11 ETIOLOGIE - ALIMENTATION
|
|
|
|
|
4.13 DÉP., DIAG. & PRONO. - PEAU
|
|
|
|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
5. TRAITEMENTS
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
Sobi to buy Novimmune R&D assets, lay off 90 staff [Fierce Biotech]
|
|
|
|
|
|
The revised deal sees Sobi buy IFNγ inhibitor emapalumab and associated assets outright. For CHF 515 million, most of which Sobi previously committed in the licensing deal, Sobi is acquiring the drug, staff involved in the clinical development of emapalumab, options on two immuno-oncology assets and a FDA priority review voucher it can either use or sell.
|
|
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
5.6 ESMO
|
|
|
|
5.9.3 EHA
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.11 PATIENTS
|
|
|
|
6.3 ASSOCIATIONS/FONDATIONS
|
|
|
|
6.4 MÉDICO-ÉCO
|
|
|
Canadian panel calls for universal public drug coverage [Reuters]
|
|
|
|
|
|
Canada is the only country with a universal health care system that does not include universal coverage for prescription drugs. Most prescriptions are paid for through employer-funded drug plans, while some are covered by government programs for the elderly, or people with low incomes or very high costs.
|
|
|
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
|
6.7.2 APPLIS
|
|
|